SCHEMBL6704775

SCHEMBL6704775

CC(C)NS(=O)(=O)c1ccc2c(c1)C(=Cc1cc3ccccc3[nH]1)C(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.54
CDK2 P24941 3/20 0.54
SRC P12931 7/20 0.52
MEN1 O00255 1/20 0.46
RGS12 O14924 1/20 0.46
NPC1 O15118 1/20 0.46
GMNN O75496 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
FYN P06241 1/20 0.46
YES1 P07947 1/20 0.46
LYN P07948 1/20 0.46
RET P07949 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704774 1.00 KDR (0.54) KDRCDK2SRCMEN1RGS12
SCHEMBL5179937 0.89 SRC (0.63) KDRCDK2SRCMEN1RGS12
SCHEMBL5179933 0.89 SRC (0.63) KDRCDK2SRCMEN1RGS12
SCHEMBL6704778 0.84 SRC (0.48) KDRCDK2SRCMEN1RGS12
Dimethylamine SCHEMBL7991352 0.84 PDPK1 (0.49) KDRSRCMEN1RGS12NPC1
SCHEMBL6394720 0.83 PDPK1 (0.65) KDRCDK2SRCMEN1RGS12
SCHEMBL6394717 0.83 PDPK1 (0.65) KDRCDK2SRCMEN1RGS12
SCHEMBL5840677 0.83 PDPK1 (0.50) KDRSRCMEN1RGS12NPC1
SCHEMBL5840674 0.83 PDPK1 (0.50) KDRSRCMEN1RGS12NPC1
SCHEMBL5182990 0.82 SRC (0.63) KDRCDK2SRCMEN1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 KDR 1857/4885CDK2 135/4885SRC 636/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 KDR 1857/4885CDK2 135/4885SRC 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.